← All trials
NCT06162013
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2028
- First posted
- Dec 8, 2023
- Last posted
- Dec 15, 2023
- Enrollment
- 330
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BergenLead sponsor
- Oslo Metropolitan UniversityCollaborator
- University of BergenOverall official - principal investigator
- Helse FonnaCollaborator
- Helse Møre og Romsdal HFCollaborator
- Nordland HospitalCollaborator
- University of OsloCollaborator
- Helse FordeCollaborator
- Vestre Viken Ringerike SykehusCollaborator
- University of BergenOfficial
- Sykehuset OstfoldCollaborator
- Elysium HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.